Status and phase
Conditions
Treatments
About
Background:
Objectives:
Eligibility:
Design:
Full description
For decades it is known that humans can be protected against malaria by repeated immunization with radiation-attenuated sporozoites. Traditionally, those sporozoites are administered by exposing the vaccinee to at least 1000 bites of sporozoite-infected irradiated mosquitoes, an approach that is unsuitable for mass vaccination campaigns. Recently, Sanaria Inc. 1 has developed a process for manufacturing, in compliance with current Good Manufacturing Practices (cGMPs) aseptic, purified, radiation attenuated cryopreserved sporozoites from a wellcharacterized isolate of P. falciparum. This product, which is called PfSPZ Vaccine, can be administered by needle and syringe. Previous studies conducted by the Vaccine Research Center, National Institutes of Health (NIH) and the Navy have established that IV administration of PfSPZ Vaccine can induce sterile protection against controlled human malaria infection (CHMI) with a homologous strain of P. falciparum in up to 100% of malaria na(SqrRoot) ve individuals.
The next logical step is to test the safety and immunogenicity of PfSPZ Vaccine in malaria experienced individuals. As an exploratory objective, this study will collect initial data to find out if the vaccine can protect against naturally occurring infection. Here, we propose a randomized double blind controlled trial to assess the safety and immunogenicity of IV administration of PfSPZ Vaccine in African adults.
Subjects will be recruited from a rural village in Mali. The study will be conducted as collaboration among the Malaria Research and Training Center (MRTC, Mali), the Laboratory of Malaria Immunology and Vaccinology (LMIV) National Institute of Allergy and Infectious Diseases (NIAID), and Sanaria, Inc. Group 1 (n=12), will receive 135,000 PfSPZ Vaccine, followed by 270,000 PfSPZ Vaccine 2 weeks later for safety purposes. An independent Data Safety Monitoring Board (DSMB) will determine whether it is safe to proceed with 270,000 PfSPZ Vaccine.
At Study Week 4, Group 4 (n=50) will receive their first of 5 doses of 270,000 PfSPZ Vaccine given at 4, 8, 12, 16, and 24 weeks, alongside Group 5 (n=50) receiving a similar volume placebo. Safety data will be collected at defined time points after each immunization. From Week 28 until Week 48 all subjects will be monitored for parasitemia detected by slide microscopy every 14 days and by passive case detection.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
The subject must satisfy all the following criteria to be eligible for the study:
EXCLUSION CRITERIA
Use of antimalarials (other than that prescribed by the investigator) or systemic antibiotics with known antimalarial activity within 30 days prior to the first vaccine dose (e.g. Trimethoprim-Sulfamethoxazole, Doxycycline, Tetracycline, Clindamycin, Erythromycin, Fluoroquinolones, or Azithromycin)
Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period
Prior receipt of a malaria vaccine candidate
Recurrent, severe infections other than malaria, and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
Use of immunoglobulins or blood products within 3 months prior to enrolment
A history of allergic disease or significant reactions against mosquito bites
Known allergies or contraindications against Artemether/Lumefantrine, or
Atovaquone/Proguanil, such as:
History of cancer (except basal cell carcinoma)
History of serious psychiatric condition that may affect participation in the study
If female: currently pregnant, lactating and / or breast-feeding
Any other serious chronic illness requiring hospital specialist supervision such as diabetes mellitus type 2.
Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 60 g per day
Suspected or known injecting drug abuse in the 5 years preceding enrolment
Any confirmed or suspected immunosuppressive or immune modulating disorder (i.e., asplenia, lupus, rheumatoid arthritis, vasculitis, sclerodermia, diabetes mellitus)
Hematuria, proteinuria, glucosuria as detected by urine dip stick above the levels defined in Appendix F
Any clinically significant abnormalities on a 12 lead ECG
Seropositive for Hepatitis B surface antigen (HBsAg)
Seropositive for Hepatitis C virus (antibodies to HCV)
Seropositive for HIV
Seropositive for Syphilis
Sickle cell trait carriage or sickle cell disease
Any clinically significant abnormal finding on biochemistry or hematology blood tests, urinalysis or clinical examination
Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the subject because of participation in the study, affect the ability of the subject to participate in the study or impair interpretation of the study data.
Primary purpose
Allocation
Interventional model
Masking
296 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal